Biosimilars cost savings: a valuable impact on health care cost

Biosimilars are expected to have a robust impact on lowering health care costs

  • Biosimilars are expected to save the EU up to $44B in health care costs by 2020.1
  • Over the next five years in the US, it is estimated that biosimilars can save the health care system $256M.2

A valuable impact on patients’ lives

More treatment options mean more patients can treat life-threatening and chronic diseases

  • As biosimilars become more widely available in the United States, they expand therapeutic options, improving the availability of treatments to patients.3

Other potential impacts and advantages of biosimilars

  • Additional services for patients
  • More options for provider education and support
  • Cost savings that can be used for investment in originator products

The value of biosimilars

Related articles and links:

References: 1. Inside Sources. Europe Demonstrates Benefits of a Strong Biosimilars Marketplace. www.insidesources.com/europe-demonstrates-benefits-strong-biosimilars-marketplace/. Accessed December 21, 2018. 2. Grewal S, Ramsay S, Balu S, Carlson JJ. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Rev of Pharmacoecon Outcomes Res. 2018;18:447-454. 3. The Biosimilars Council. Biosimilars in the United States. Providing More Patients Greater Access to Lifesaving Medicines. www.biosimilarscouncil.org/wp-content/uploads/2017/09/Biosimilars-Council-Patient-Access-Study_090917.pdf. Accessed December 21, 2018.